[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-345995-105":59,"doc-detail-345995-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","metabolic-modulation-in-cancer-care-the-potential-role-of-glucagon-like-peptide-1-receptor-agonists","Metabolic Modulation in Cancer Care - The Potential Role of Glucagon-Like Peptide-1 Receptor Agonists","","Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have transformed management of type 2 diabetes and obesity, delivering sustained glycemic improvement, weight loss, and cardiovascular benefits. These effects have stimulated interest in cancer therapy. Obesity and metabolic dysfunction drive cancer development, progression, and treatment resistance, supporting a plausible anticancer role for pathway-targeting drugs. Epidemiologic and clinical data associate GLP-1RA use with lower risk of obesity-related cancers. Mechanistic work indicates impacts on insulin signaling, chronic inflammation, angiogenesis, and immune regulation.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/metabolic-modulation-in-cancer-care-the-potential-role-of-glucagon-like-peptide-1-receptor-agonists/345995/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/metabolic-modulation-in-cancer-care-the-potential-role-of-glucagon-like-peptide-1-receptor-agonists/345995.png","ImageObject",300,407,{"name":92,"@type":93},"Clementine","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"为什么GLP-1受体激动剂（GLP-1RAs）会被认为可能与肿瘤治疗相关？","Question",{"text":113,"@type":114},"文章指出肥胖和代谢失调是多种癌症发生、进展及治疗耐药的重要因素；而GLP-1RAs可影响胰岛素信号、长期炎症、血管生成与免疫调节等机制，从而提供潜在抗癌通路。","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"有哪些流行病学与临床证据支持GLP-1RAs与部分癌症风险降低有关？",{"text":118,"@type":114},"文章总结了新兴流行病学与临床证据，提示GLP-1RA治疗与多种与肥胖相关癌症风险更低相关，包括胃肠道、生殖系统及血液系统肿瘤等。",{"name":120,"@type":111,"acceptedAnswer":121},"文章如何评估GLP-1RAs在癌症中的应用场景与潜在策略？",{"text":122,"@type":114},"综述整合药物作用、流行病学、机制与临床应用证据，评估其在癌症预防、作为补充治疗以及既往确诊癌症患者中的结局表现，并提出可能用于新辅助治疗策略，尤其在新辅助间隔较长、可在手术前进行代谢优化的情境。","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},345995,1790190491,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1374391974564,"https://ap-avatar.wpscdn.com/avatar/14000253aa45c000a9e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779874745381141002","Review Articles  \nMetabolic Modulation in Cancer Care: The Potential Role of  \nGlucagon-Like Peptide-1 Receptor Agonists  \nHugo C. Temperley, MB, BCh, BAO MCh1,2  and Michael E. Kelly, PhD, FRCSI2,3,4  DOI [https://doi.org/10.1200/JCO-26-00062](https://doi.org/10.1200/JCO-26-00062)  \nABSTRACT  \nGlucagon-like peptide-1 receptor agonists (GLP-1RAs) have revolutionized the management of type 2 diabetes and obesity by providing sustained improvements in glycemic control, weight loss, and cardiovascular outcomes. These beneﬁts have led to increasing interest in their potential role in cancer treatment. Obesity and metabolic dysfunction are well-known factors that promote the development, progression, and resistance to therapy in various cancers, suggesting that drugs targeting these pathways may have anticancer effects. Emerging epidemiologic and clinical evidence shows that GLP-1RA therapy is linked to a lower risk of several obesity-related cancers, including GI, breast, endometrial, ovarian, prostate, and hematologic malignancies. Mechanistic studies also reveal effects on insulin signaling, long-term inﬂammation, angiogenesis, and immune system modulation. This comprehensive review integrates current knowledge of GLP-1RAs in cancer care, covering drug action, epidemiology, underlying mechanisms, and clinical application. We evaluate evidence for cancer prevention, their use as complementary treatments, and outcomes in patients with existing cancer. Overall, the evidence suggests that GLP-1RAs could become a novel class of agents linking metabolic health and cancer therapy, with potential applications in neoadjuvant treatment strategies, particularly in settings where prolonged neoadjuvant intervals allow for metabolic optimization before deﬁnitive surgical intervention.  \nAccepted May 19, 2026 Published June 29, 2026  \nJ Clin Oncol 44:2244-2252 © 2026 by American Society of Clinical Oncology  \nView Online Article  \nCreative Commons Attribution Non-Commercial No Derivatives 4.0 License  \nINTRODUCTION  \nCancer incidence continues to rise worldwide, with obesity and metabolic dysfunction emerging as key modiﬁable risk factors.1 Excess adiposity accounts for about 20% of cancer-related deaths globally, mainly through its effects on insulin resistance, inﬂammation, and hormonal imbalance.2 Alongside these epidemiologic trends, glucagonlike peptide-1 receptor agonists (GLP-1RAs), initially created for glucose control in type 2 diabetes (T2D), are now widely used for obesity treatment.3 Among adults in the United States, 6% report current use and 12% report current or past use; this rises to 22% among those diagnosed with overweight or obesity by a clinician.4  \nThis expansion has strengthened the connection between endocrinology and oncology. An increasing number of patients with cancer are now prescribed GLP-1RAs at diagnosis or during treatment, and observational studies increasingly indicate that GLP-1RAs may lower cancer risk and improve patient outcomes.5-7 Concurrently, mechanistic research shows effects on tumor cell growth, blood vessel formation, and immune evasion, highlighting possible biologic pathways for anticancer activity.8,9  \nGiven the growing clinical importance of GLP-1RAs, this review provides a comprehensive overview of their role in  \noncology. We analyze pharmacology and mechanisms, summarize epidemiologic and clinical evidence across cancer types, discuss safety considerations, and explore future directions for incorporating GLP-1RAs into cancer prevention and treatment.  \nWhat Are GLP-1RAs?  \nGLP-1RAs are synthetic analogues of the GLP-1 hormone, which binds to the GLP-1 receptor and helps regulate blood sugar levels and satiety signals.10 The GLP-1 receptor is primarily expressed on pancreatic beta cells. In the presence of glucose, this binding stimulates insulin release and suppresses glucagon secretion, thereby improving glucose uptake in the periphery.11 In nonhuman primates, GLP-1 receptor expression w","cbCaiiHVHlcXYpKj","https://ap.wps.com/l/cbCaiiHVHlcXYpKj","pdf",1026738,"English","# Abstract\n## Introduction\n## What Are GLP-1RAs?\n## GLP-1 Receptor Agonists in Cancer Care\n## T2D and Obesity in Cancer","[{\"question\":\"为什么GLP-1受体激动剂（GLP-1RAs）会被认为可能与肿瘤治疗相关？\",\"answer\":\"文章指出肥胖和代谢失调是多种癌症发生、进展及治疗耐药的重要因素；而GLP-1RAs可影响胰岛素信号、长期炎症、血管生成与免疫调节等机制，从而提供潜在抗癌通路。\"},{\"question\":\"有哪些流行病学与临床证据支持GLP-1RAs与部分癌症风险降低有关？\",\"answer\":\"文章总结了新兴流行病学与临床证据，提示GLP-1RA治疗与多种与肥胖相关癌症风险更低相关，包括胃肠道、生殖系统及血液系统肿瘤等。\"},{\"question\":\"文章如何评估GLP-1RAs在癌症中的应用场景与潜在策略？\",\"answer\":\"综述整合药物作用、流行病学、机制与临床应用证据，评估其在癌症预防、作为补充治疗以及既往确诊癌症患者中的结局表现，并提出可能用于新辅助治疗策略，尤其在新辅助间隔较长、可在手术前进行代谢优化的情境。\"}]","Metabolic Modulation in Cancer Care - The Potential Role of Glucagon-Like Peptide-1 Receptor Agonists | PDF",1790059631,25,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/549a6add03814eb341899545d5e88c16.webp",983,1315,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8446adeb0ff642e3decce3fa707eb8bc.webp",982,1314,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6df2b47a6b483de3136e111008c56267.webp",981,1312,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a941a3defdab57eddc513b000d6cfca8.webp",980,1311]